Neurocrine Biosciences (NBIX) Accumulated Expenses (2010 - 2019)

Neurocrine Biosciences' Accumulated Expenses history runs 10 years deep, the most recent figure standing at $38.9 million for Q4 2019.

• Quarterly Accumulated Expenses rose 42.43% year-over-year to $38.9 million in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $38.9 million (up 42.43% YoY) and the FY2019 annual result came in at $38.9 million, up 42.43% from the prior year.
• Accumulated Expenses was $38.9 million for Q4 2019 at Neurocrine Biosciences, up from $27.3 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $38.9 million in Q4 2019 and bottomed at $7.4 million in Q4 2015.
• A 5-year average of $18.5 million and a median of $17.8 million in 2016 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2015 — Accumulated Expenses tumbled 36.06% — and 2017, when it soared 160.5%.
• Neurocrine Biosciences' Accumulated Expenses stood at $7.4 million in 2015, then gained by 29.91% to $9.6 million in 2016, then surged by 160.5% to $24.9 million in 2017, then increased by 9.8% to $27.3 million in 2018, then soared by 42.43% to $38.9 million in 2019.
• Business Quant data shows NBIX's Accumulated Expenses at $38.9 million in Q4 2019, $27.3 million in Q4 2018, and $24.9 million in Q4 2017.